IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.
Status:
Not yet recruiting
Trial end date:
2023-06-20
Target enrollment:
Participant gender:
Summary
The Phase Ia study was designed to evaluate the tolerability, safety, PK, PD, immunogenicity
and primary resistance of single therapy tumor activity in subjects with advanced or
metastatic solid tumors who have failed standard treatment. Phase Ib study was designed to
evaluate the safety and initial efficacy of IBI322 in monotherapy or combination therapy in
subjects with advanced or metastatic solid tumors. Investigators and sponsors determine the
recommended dose of IBI322 for phase Ib based on PK, PD, safety and efficacy data obtained
during phase Ia.